Journals / art / 2020 / Cilt: 35 - Sayı: 3

The Effects of Tofacitinib-Mediated Janus Kinase/Signal Transducers and Activators of the Transcription Signal Pathway Inhibition on Collagen Biosynthesis in Hepatic and Skin Fibroblast Cell Culture

Journal
art
Pages
343–350
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, further extensive animal and human studies are necessary to determine the clinical significance of this effect.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: This study aims to investigate the effects of Janus kinase/signal transducers and activators of the transcription (JAK/STAT) pathway inhibition on collagen biosynthesis in fibroblast cell culture by tofacitinib.
📊
Key Findings & Data:Materials and methods: BJ-CRL-1474® (skin) and BRL3A® (hepatic) fibroblast cell cultures were proliferated in a suitable medium.
💡
Conclusion & Impact:However, further extensive animal and human studies are necessary to determine the clinical significance of this effect.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Objectives: This study aims to investigate the effects of Janus kinase/signal transducers and activators of the transcription (JAK/STAT) pathway inhibition on collagen biosynthesis in fibroblast cell culture by tofacitinib. Materials and methods: BJ-CRL-1474® (skin) and BRL3A® (hepatic) fibroblast cell cultures were proliferated in a suitable medium. Tofacitinib was administered to fibroblast cells proliferating in 96-well flasks at concentrations of 25, 50, 100, 200, 400, and 800 nM. Tissue inhibitor of metalloproteinase-1 (TIMP-1), matrix metalloproteinase-3 (MMP-3), transforming growth factor beta 1 (TGF-β1), and hydroxyproline levels were measured using the enzyme-linked immunosorbent assay method. Results: Tofacitinib showed cytotoxic effect on skin and liver cell culture. The cytotoxic effect of tofacitinib started at 100 nM (p<0.05). The highest effect was obtained at 800 nM. The time-dependent cytotoxic effect of tofacitinib was significantly higher at all concentrations after 72 hours than at 24 and 48 hours (p<0.05). The level of TGF-β1 was significantly lower even at a tofacitinib concentration of 25 nM (p<0.05). There were significant decreases in MMP-3, TIMP-1, and hydroxyproline levels after tofacitinib administration (p<0.05). Conclusion: Tofacitinib inhibited fibroblast cell proliferation in a concentration-dependent manner in a fibroblast cell culture. However, further extensive animal and human studies are necessary to determine the clinical significance of this effect.

🔖

Cite This Article

ŞAHİN, M., AYDIN, H., ALTUN, A., DERİN, M. E., ŞAHİN, A. (2020). The Effects of Tofacitinib-Mediated Janus Kinase/Signal Transducers and Activators of the Transcription Signal Pathway Inhibition on Collagen Biosynthesis in Hepatic and Skin Fibroblast Cell Culture. art, Cilt: 35 - Sayı: 3, 343–350. https://ajindex.com/articles/142821

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Turanlıgil S, Ceren N, Uyanıkgil Y. Hücre içi sinyal yolakları ve klinik yansımaları. Ariv 2010;19:180-91.
  2. Derynck R, Zhang YE. Smad-dependent and Smadindependent pathways in TGF-beta family signalling. Nature 2003;425:577-84.
  3. Kuralay F, Çavdar Z. ‹nflamatuar medyatörlere toplu bir bakış. Genel Tıp Derg 2006;16:143-52. Pawson T. Regulation and targets of receptor tyrosine kinases. Eur J Cancer 2002;38 Suppl 5:S3-10. Leask A, Abraham DJ. TGF-beta signaling and the fibrotic response. FASEB J 2004;18:816-27.
  4. Vainchenker W, Constantinescu SN. JAK/STAT signaling in hematological malignancies. Oncogene 2013;32:2601-13.
  5. Rawlings JS, Rosler KM, Harrison DA. The JAK/ STAT signaling pathway. J Cell Sci 2004;117:1281-3.
  6. Wu W, Sun XH. Janus kinase 3: the controller and the controlled. Acta Biochim Biophys Sin 2012;44:187-96.
  7. Distler O, Cozzio A. Systemic sclerosis and localized scleroderma--current concepts and novel targets for therapy. Semin Immunopathol 2016;38:87-95.
  8. Boyle DL, Soma K, Hodge J, Kavanaugh A, Mandel D, Mease P, et al. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis. Ann Rheum Dis 2015;74:1311-6.
  9. Ghoreschi K, Jesson MI, Li X, Lee JL, Ghosh S, Alsup JW, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol 2011;186:4234-43.
  10. Pedroza M, Le TT, Lewis K, Karmouty-Quintana H, To S, George AT, et al. STAT-3 contributes to pulmonary fibrosis through epithelial injury and fibroblast-myofibroblast differentiation. FASEB J 2016;30:129-40.
  11. Dong Z, Zhao X, Tai W, Lei W, Wang Y, Li Z, et al. IL-27 attenuates the TGF-b1-induced proliferation, differentiation and collagen synthesis in lung fibroblasts. Life Sci 2016;146:24-33. Masamune A1, Satoh M, Kikuta K, Suzuki N, Shimosegawa T. Activation of JAK-STAT pathway is required for platelet-derived growth factor-induced proliferation of pancreatic stellate cells. World J Gastroenterol 2005;11:3385-91.
  12. Gu YJ, Sun WY, Zhang S, Li XR, Wei W. Targeted blockade of JAK/STAT3 signaling inhibits proliferation, migration and collagen production as well as inducing the apoptosis of hepatic stellate cells. Int J Mol Med 2016;38:903-11.
  13. Yan J, Zhang Z, Yang J, Mitch WE, Wang Y. JAK3/ STAT6 Stimulates Bone Marrow-Derived Fibroblast Activation in Renal Fibrosis. J Am Soc Nephrol 2015;26:3060-71.
  14. Cada DJ, Demaris K, Levien TL, Baker DE. Tofacitinib. Hosp Pharm 2013;48:413-24.
  15. Meng XM, Nikolic-Paterson DJ, Lan HY. TGF-b: the master regulator of f